Cypherpunk Technologies Inc.

CYPH· Nasdaq

Since Oct 5, 2025

Transactions: 9
Purchases: 0
Sales: 9
Purchase value: $0.00
Sale value: $3.06M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Oei Khing DjienDirector

Filed Sep 25, 2026Period of report Sep 25, 20260001104659-26-111063

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleSep 25, 2026	Common Stock^F1	168,750	$3.92	$661.50K	0	Direct

Filing footnotes · 1

F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the settlement of restricted stock units.

Open on SEC EDGAR

Martin Patricia A.Director

Filed Sep 25, 2026Period of report Sep 23, 20260001104659-26-111061

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleSep 23, 2026	Common Stock^F1	50,000	$3.86	$193.00K	118,750	Direct

Dietz Thomas JohnDirector

Filed Aug 27, 2026Period of report Aug 26, 20260001104659-26-102467

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleAug 26, 2026	Common Stock	20,000	$1.72	$34.40K	132,500	Direct

Mirabelli ChristopherDirector

Filed Mar 30, 2026Period of report Mar 26, 20260001104659-26-036804

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleMar 26, 2026	Common Stock^F1	60,000	$0.7105	$42.63K	130,376	Direct

Mirabelli ChristopherDirector

Filed Nov 19, 2025Period of report Nov 17, 20250001104659-25-114094

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleNov 17, 2025	Common Stock^F1^F2^F4	261,840	$3.14	$822.18K

Cavanaugh James HDirector

Filed Nov 19, 2025Period of report Nov 17, 20250001104659-25-114093

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleNov 17, 2025	Common Stock^F1^F2	261,840	$3.14	$822.18K	0

Onsi Douglas eDirector · CEO,CFO,Pres.,GC,Treas.&Sec.

Filed Nov 19, 2025Period of report Nov 17, 20250001104659-25-114084

Transaction	Security	Shares	Price	ValueValue (shares × price)	Held after	Ownership
SaleNov 17, 2025	Common Stock^F1^F2^F4	261,840	$3.14	$822.18K

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.

Filing footnotes · 4

F1On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.
F2On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.
F3Reflects a de minimis adjustment of one (1) share due to rounding.
F4The reporting person is a managing member of Nine Capital Partners and may be deemed to have beneficial ownership of such 2,136 shares of common stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have had beneficial ownership of the 414,479 shares of Common Stock sold by HCV IX. The reporting person is a beneficiary of the HCV Liquidating Trust and may be deemed to have had beneficial ownership of the 261,840 shares of Common Stock sold by the HCV Liquidating Trust. The reporting person disclaims beneficial ownership of such shares of common stock held by Nine Capital Partners, and sold by each of HCV IX and the HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.

Filing footnotes · 4

F1On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.
F2On November 17, 2025, HealthCare Ventures IX, L.P. ("HCV IX") sold 414,479 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.
F3Reflects a de minimis adjustment of one (1) share due to rounding.
F4The reporting person is a managing member of Nine Capital Partners and may be deemed to have beneficial ownership of such 2,136 shares of common stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have had beneficial ownership of the 414,479 shares of Common Stock sold by HCV IX. The reporting person is a beneficiary of the HCV Liquidating Trust and may be deemed to have had beneficial ownership of the 261,840 shares of Common Stock sold by the HCV Liquidating Trust. The reporting person disclaims beneficial ownership of such shares of common stock held by Nine Capital Partners, and sold by each of HCV IX and the HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.